# Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial

Source: https://onco.cc/trials/nct05701436/  
OnCo record `nct05701436` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Oxaliplatin, Doxorubicin, Cisplatin and Raltitrexed in Hepatocellular carcinoma, run by Zhujiang Hospital, with a status the registry has not verified recently.

## Summary

Applicability of 3D-HDRA in Patients With Primary Liver Cancer: A Randomized Controlled Trial is a phase 3 interventional study registered as NCT05701436 by Zhujiang Hospital, with 144 participants planned, started 2022-09-01 and due to reach its primary completion in 2026-01-01. Interventions recorded: Oxaliplatin, Doxorubicin, Lobaplatin, Cisplatin, Oxaliplatin, Leucovorin, fluorouracil, Lobaplatin, Raltitrexed. Conditions recorded: Liver, Cancer of, Primary Resectable.

Linked to the drug Raltitrexed because the registry names it among its interventions and Hepatocellular carcinoma among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05701436
- Phase: 3
- Setting: Applicability of 3D Histoculture Drug Response Assay(3D-HDRA) in Patients With Primary Liver Cancer: A Randomized Controlled Trial
- Sponsor: Zhujiang Hospital
- Enrolled: 144

## Sources

- ClinicalTrials.gov NCT05701436: https://clinicaltrials.gov/study/NCT05701436

## Connected records

- cancers: [Hepatocellular carcinoma](https://onco.cc/cancers/hcc/)
- drugs: [Cisplatin](https://onco.cc/drugs/cisplatin/), [Doxorubicin](https://onco.cc/drugs/doxorubicin/), [Oxaliplatin](https://onco.cc/drugs/oxaliplatin/), [Raltitrexed](https://onco.cc/drugs/raltitrexed/)

---
JSON: https://onco.cc/api/v1/entities/nct05701436.json